Scope of the research:
- Annualized data on the seven key Neuroendocrine carcinoma markets revenue data (the US, France, Germany, Italy, Spain, the UK and Japan) from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data showing a split across the different phases, mechanisms of action being developed and emerging trends in the market. Pipeline candidates fall under the following mechanisms of action: Somatostatin analogues and Vascular Endothelial Growth Factor (VEGF) inhibitors, insulin-like growth factor-1 receptor (IGFR-1) inhibitors, tyrosine kinase inhibitor (TKI) and Smoothened (Smo) inhibitor.
- Analysis of the current and future competition in the global Neuroendocrine carcinoma market. Key market players covered are Novartis AG, Roche, the Eli Lilly & Company, Callisto Pharmaceuticals, Molecular Insight pharmaceuticals, Advanced Accelerator Applications S.A, Roche, Ipsen and Amgen Inc.
- Insightful review of the key drivers, restraints and challenges in the Neuroendocrine Carcinoma Therapeutics Market . Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, market characterization, and unmet needs and their implications for the Neuroendocrine carcinoma therapeutics market.
- Analysis of key recent licensing and partnership agreements in the Neuroendocrine carcinoma market.
To view the detailed table of contents for this report please click - Neuroendocrine Carcinoma Therapeutics Market Report or visit http://www.rep
Copyright©2012 PR Newswire.
All rights reserved